Background: Amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s diseases are age-related neurodegenerative diseases. ALS is not a single entity but a syndrome with many different causes. In all 3 diseases, gene mutations account for only 10–15% of cases. Many environmental and lifestyle factors have been implicated as risk factors for ALS, though none have been proven to cause the disease. It is generally believed that ALS results from interactions between environmental risk factors and genetic predisposing factors. The advent of next-generation sequencing and recent advances in research into environmental risk factors offer the opportunity to investigate these interactions. Summary: We propose a hypothesis to explain the syndrome of ALS based on the interaction of many individual environmental risk factors with many individual genetic predisposing factors. We hypothesize that there are many such combinations of individual, specific, genetic, and environmental factors, and that each combination can lead to the development of the syndrome of ALS. We also propose a hypothesis that explains the overlap between the age-related neurodegenerations and their genetic underpinnings. Age and duration of exposure are crucial factors in these age-related neurodegenerative diseases, and we consider how these may relate to gene-environment interactions. Key Messages: To date, genetic studies and environmental studies have investigated the causes of ALS separately. We argue that this univariate approach will not lead to discoveries of important gene-environment interactions. We propose new research approaches to investigating gene-environment interactions based on these hypotheses.

Keywords:
Amyotrophic lateral sclerosis, Gene-environment-time interactions, Neurodegenerative diseases, Environmental risk factors, Genetic predisposition
1.
Abrahao A, Abath Neto O, Kok F, et al: One family, one gene and three phenotypes: a novel VCP (valosin-containing protein) mutation associated with myopathy with rimmed vacuoles, amyotrophic lateral sclerosis and frontotemporal dementia. J Neurol Sci 2016; 368: 352–358.
2.
Nicholson AM, Rademakers R: What we know about TMEM106B in neurodegeneration. Acta Neuropathol 2016; 132: 639–651.
3.
Nicolas A, Kenna KP, Renton AE, et al: Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 2018; 97: 1268–1283.e6.
4.
Ali O: Genetics of type 2 diabetes. World j Diabetes 2013; 4: 114–123.
5.
Wild CP: Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005; 14: 1847–1850.
6.
Traynor BJ, Singleton AB: Nature versus nurture: death of a dogma, and the road ahead. Neuron 2010; 68: 196–200.
7.
Al-Chalabi A, Hardiman O: The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013; 9: 617–628
8.
Hägerstrand T: Reflections on “What About People in Regional Science?” Papers of the Regional Science Association 1989, vol 66, pp 1–6.
9.
Jacquez GM, Sabel CE, Shi C: Genetic GIScience: toward a place-based synthesis of the genome, exposome, and behavome. Ann Assoc Am Geogr 2015; 105: 454–472.
10.
Smith AH, Marshall G, Roh T, et al: Lung, bladder, and kidney cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst 2018; 110: 241–249.
11.
Seals RM, Hansen J, Gredal O, et al: Age-period-cohort analysis of trends in amyotrophic lateral sclerosis in Denmark, 1970-2009. Am J Epidemiol 2013; 178: 1265–1271.
12.
Henry KA, Fagliano J, Jordan HM, et al: Geographic variation of amyotrophic lateral sclerosis incidence in New Jersey, 2009-2011. Am J Epidemiol 2015; 182: 512–519.
13.
Driver JA, Logroscino G, Gaziano JM, et al: Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72: 432–438.
14.
Savica R, Grossardt BR, Bower JH, et al: Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord 2017; 32: 227–234.
15.
Kawas C, Gray S, Brookmeyer R, et al: Age-specific incidence rates of Alzheimer’s disease: the baltimore longitudinal study of aging. Neurology 2000; 54: 2072–2077.
16.
Vardarajan BN, Faber KM, Bird TD, et al: Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). JAMA Neurol 2014; 71: 315–323.
17.
Al-Chalabi A, Calvo A, Chio A, et al: Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014; 13: 1108–1113.
18.
Li HF, Wu ZY: Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl Neurodegener 2016; 5: 3.
19.
Chiò A, Mazzini L, D’Alfonso S, et al: The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018; 91:e635–e642.
20.
Meltz Steinberg K, Nicholas TJ, Koboldt DC, et al: Whole genome analyses reveal no pathogenetic single nucleotide or structural differences between monozygotic twins discordant for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 385–392.
21.
Román GC: Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. J Neurol Neurosurg Psychiatry 1996; 61: 131–137.
22.
Garutto RM: Lessons from the study of natural experiments of hyperdendemic foci of neurodegeneration; in Amyotrophic lateral sclerosis and the frontotemporal dementias. Chap 1, Oxford University Press 2012, pp 1–26.
23.
Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci U S A 2004; 101: 12228–12231.
24.
Murch SJ, Cox PA, Banack SA, et al: Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 2004; 110: 267–269.
25.
Banack SA, Cox PA: Creating a simian model of guam ALS/PDC which reflects chamorro lifetime BMAA exposures. Neurotox Res 2018; 33: 24–32.
26.
Burggren WW: Dynamics of epigenetic phenomena: intergenerational and intragenerational phenotype ‘washout’. J Exp Biol 2015; 218(pt 1): 80–87.
27.
Shi X: A geocomputational process for characterizing the spatial pattern of lung cancer incidence in new hampshire. Annals of the Association of American Geographers 2009; 99: 521–533.
28.
Torbick N, Ziniti B, Stommel E, Linder E, Andrew A, Caller T, et al: Assessing cyanobacterial harmful algal blooms as risk factors for amyotrophic lateral sclerosis. Neurotox Res 2018; 199–212.
29.
Gibson G: Population genetics and GWAS: a primer. PLoS Biol 2018; 16:e2005485.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.